<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Bioeng. Biotechnol.</journal-id>
<journal-title>Frontiers in Bioengineering and Biotechnology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Bioeng. Biotechnol.</abbrev-journal-title>
<issn pub-type="epub">2296-4185</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1071776</article-id>
<article-id pub-id-type="doi">10.3389/fbioe.2022.1071776</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Bioengineering and Biotechnology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Flavokawain A alleviates the progression of mouse osteoarthritis: An <italic>in vitro</italic> and <italic>in vivo</italic> study</article-title>
<alt-title alt-title-type="left-running-head">Jing et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fbioe2022.1071776">10.3389/fbioe2022.1071776</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Jing</surname>
<given-names>Shaoze</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2020529/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wan</surname>
<given-names>Junlai</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1531788/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Tianqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1515669/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Zhiyi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1411600/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ding</surname>
<given-names>Qing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sheng</surname>
<given-names>Gaohong</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1486952/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shanxi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2056366/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Hongqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Ziqing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wu</surname>
<given-names>Hua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1321478/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Wenkai</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Orthopedics</institution>, <institution>Tongji Hospital</institution>, <institution>Tongji Medical College</institution>, <institution>Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Third Hospital of Shanxi Medical University</institution>, <institution>Shanxi Bethune Hospital</institution>, <institution>Shanxi Academy of Medical Sciences</institution>, <institution>Tongji Shanxi Hospital</institution>, <addr-line>Taiyuan</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/805550/overview">Gina Lisignoli</ext-link>, Rizzoli Orthopedic Institute (IRCCS), Italy</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/802125/overview">Giovanna Desando</ext-link>, Rizzoli Orthopedic Institute (IRCCS), Italy</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/899577/overview">Elisa Assirelli</ext-link>, Rizzoli Orthopedic Institute (IRCCS), Italy</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Hua Wu, <email>wuhua@hust.edu.cn</email>; Wenkai Li, <email>bluesky727@163.com</email>
</corresp>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other">
<p>This article was submitted to Tissue Engineering and Regenerative Medicine, a section of the journal Frontiers in Bioengineering and Biotechnology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>10</volume>
<elocation-id>1071776</elocation-id>
<history>
<date date-type="received">
<day>16</day>
<month>10</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>11</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Jing, Wan, Wang, He, Ding, Sheng, Wang, Zhao, Zhu, Wu and Li.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Jing, Wan, Wang, He, Ding, Sheng, Wang, Zhao, Zhu, Wu and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Osteoarthritis (OA) is one of the most prevalent chronic degenerative joint diseases affecting adults in their middle or later years. It is characterized by symptoms such as joint pain, difficulty in movement, disability, and even loss of motion. Moreover, the onset and progression of inflammation are directly associated with OA. In this research, we evaluated the impact of Flavokawain A (FKA) on osteoarthritis. <italic>In-vitro</italic> effects of FKA on murine chondrocytes have been examined using cell counting kit-8 (CCK-8), safranin o staining, western blot, immunofluorescence staining, senescence &#x3b2;-galactosidase staining, flow cytometry analysis, and mRFP-GFP-LC3 adenovirus infection. An <italic>in-vivo</italic> model of destabilization of the medial meniscus (DMM) was employed to investigate FKA&#x2019;s effect on OA mouse. An analysis of bioinformatics was performed on FKA and its potential role in OA. It was observed that FKA blocked interleukin (IL)-1&#x3b2;-induced expression of inflammatory factors, i.e., cyclooxygenase-2 (COX2) and inducible nitric oxide synthase (iNOS) in chondrocytes. In addition, FKA also downregulated the catabolic enzyme expression, i.e., aggrecanase-2 (ADAMTS5) and matrix metalloproteinases (MMPs), and helped in the upregulation of the anabolic protein expression, i.e., type II collagen (Col2), Aggrecan, and sry-box transcription factor 9 (SOX9). Moreover, FKA ameliorated IL-1&#x3b2;-triggered autophagy in chondrocytes, and it was observed that the FKA causes anti-inflammatory effects by the mitogen-activated protein kinase (MAPK) and phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathways inhibition. The results of immunohistochemical analysis and microcomputed tomography from the <italic>in vivo</italic> OA mouse model confirmed the therapeutic effect of FKA. Finally, we assessed the anti-arthritic impacts of FKA by conducting <italic>in vivo</italic> and <italic>in vitro</italic> analyses. We concluded that FKA can be employed as a useful therapeutic agent for OA therapy, but the findings require needs further clinical investigation.</p>
</abstract>
<kwd-group>
<kwd>flavokawain A</kwd>
<kwd>osteoarthritis</kwd>
<kwd>apoptosis</kwd>
<kwd>autophagy</kwd>
<kwd>3-methyladenine</kwd>
<kwd>MAPK</kwd>
<kwd>PI3K/AKT/mTOR</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content>
</contract-sponsor>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Osteoarthritis (OA) is one of the most prevalent joint diseases around the globe. Around 18% of women and 10% of men over 60 years of age are affected by it (<xref ref-type="bibr" rid="B34">Woolf and Pfleger, 2003</xref>). The most common clinical features of OA are joint pain, swelling, stiffness, and subchondral bone sclerosis (<xref ref-type="bibr" rid="B1">Aicher and Rolauffs, 2014</xref>). Non-steroidal anti-inflammatory drugs (NSAIDs) are the main drug of choice for the conservative treatment of OA. But NSAIDs have some significant side effects, including gastrointestinal irritation, ulceration and bleeding (<xref ref-type="bibr" rid="B18">Katz et al., 2021</xref>). The treatment of end-stage OA is knee arthroplasty, but the functional results may be poor, and the life of the prosthesis is limited (<xref ref-type="bibr" rid="B13">Glyn-Jones et al., 2015</xref>). Therefore, the focus of OA research has shifted to prevention and early treatment. Drug development for joint protection interventions is in progress. Cartilage metabolic imbalance and chronic inflammatory responses are critical in the progression of OA (<xref ref-type="bibr" rid="B3">Appleton, 2018</xref>). Increased levels of the proinflammatory cytokine IL-1&#x3b2;, which promotes the cartilage matrix catabolic enzyme synthesis, such as ADAMTS5 and MMPs (<xref ref-type="bibr" rid="B21">Le Maitre et al., 2007</xref>), and suppresses the levels of important extracellular matrix (ECM) proteins, including Col2 and Aggrecan (<xref ref-type="bibr" rid="B19">Kobayashi et al., 2005</xref>), were detected in the synovial fluid of individuals suffering from OA (<xref ref-type="bibr" rid="B7">Chen et al., 2020</xref>). Therefore, drugs that reverse the IL-1&#x3b2;&#x2032;s effect can help in designing a potential therapy for OA.</p>
<p>In recent years, plant extracts have been recognized for their pharmaceutical significance. Flavokawain A (FKA) is a natural chalcone extracted from Piper methysticum Forst, which has exhibited anti-apoptotic and anti-inflammatory effects (<xref ref-type="bibr" rid="B31">Rajendran et al., 2021</xref>). The <italic>in vitro</italic> studies have revealed that FKA inhibits the NF&#x3ba;B and MAPK pathways to relieve lipopolysaccharide-induced inflammation of Raw 264.7 macrophages (<xref ref-type="bibr" rid="B20">Kwon et al., 2013</xref>). Furthermore, the ability of FKA to regulate oxidative stress has been published (<xref ref-type="bibr" rid="B15">Hseu et al., 2019</xref>). However, the role of FKA in OA has not yet been investigated. Hence, the objective of this research is to elucidate the possible role of FKA in OA treatment.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Ethics approval</title>
<p>For the purpose of minimizing animal suffering, the research was conducted as per the guiding principles and protocols established by the Animal Care and Use Committee for Teaching and Research at the Tongji Medical College of Huazhong University of Science and Technology.</p>
</sec>
<sec id="s2-2">
<title>Chemicals and materials</title>
<p>FKA (T3S0737, purity: 99.41%) and 3-Methyladenine (3&#xa0;MA) were acquired from TOPSCIENCE (Shanghai, China), and the mouse IL-1&#x3b2; cytokine was obtained from the R&#x26;D system (501-RL-010, United States). Safranin O solution were provided by Solarbio (Beijing, China). The primary antibodies for iNOS, COX2, Col2, Aggrecan, Sox9, and immunofluorescence secondary antibodies were acquired from Abcam (Shanghai, China). Atg12, Beclin, LC3I/II, P21, P16, Bax, Bcl2, GAPDH, and antibodies for all pathways were purchased from CST (Beverly, MA, United States). Corresponding primary antibodies for MMP3/13 and Nrf2/HO-1/NQO1 were supplied by the Proteintech Group (Wuhan, Hubei, China). ADAMTS5 primary antibody, secondary antibody, phosphate-buffered saline (PBS), trypsin, collagenase type II, the CCK8 assay kit, bovine serum albumin (BSA), and protein extraction kit were ordered and acquired from Boster Biological Technology (Wuhan, Hubei, China). RFP-GFP-LC3-adenovirus was purchased from Hanbio (Shanghai, China). The Senescence &#x3b2;-galactosidase staining kit and the Annexin V-FITC apoptosis detection kit were supplied by Beyotime (Shanghai, China).</p>
</sec>
<sec id="s2-3">
<title>Isolation and culture of chondrocytes</title>
<p>In our study, five-day-old male C57BL/6J mice were sacrificed to obtain chondrocytes. The cartilage was obtained from around the knee joint region of the mice and was cut into granules after removing the surrounding synovial tissue. The granules were digested with trypsin for half an hour. Later, 0.2% type II collagenase was added for digestion for a period of 6&#xa0;h. Subsequently, the cell suspension was concentrated by the process of centrifugation at 300g for a period of 5&#xa0;min to obtain primary chondrocytes. Moreover, the incubation of primary chondrocytes was performed at a temperature of 37&#xb0;C, with 5% CO<sub>2</sub> in DMEM/F12 (1:1) medium containing penicillin/streptomycin solution (1%) and FBS (10%). The cells of the third passage were utilized for subsequent experiments.</p>
</sec>
<sec id="s2-4">
<title>Cell viability assay</title>
<p>For the measurement of the viability of cells, the CCK8 assay was employed. Mouse chondrocytes were seeded at a density of 1&#xd7;10<sup>4</sup> cells/well in a 96-well plate containing the required culture medium. Following cell adhesion, 0.1&#xa0;ml of medium with or without IL-1&#x3b2; (5&#xa0;ng/ml) was added at various concentrations of FKA (0, 5, 10, 20, and 40&#xa0;&#x3bc;M) for a period of 24&#xa0;h. Subsequently, an addition of 10&#xa0;&#x3bc;l of CCK 8 solution was carried out in all the wells, and incubation was performed for a period of 1&#xa0;h. Thereafter, we employed a microplate reader (Bio-Rad, Richmond, CA, United States) to measure the viability of cells by measuring the absorbance at 450&#xa0;nm.</p>
</sec>
<sec id="s2-5">
<title>Safranin O staining</title>
<p>Seeding of chondrocytes was performed in 24-well plates. When chondrocytes reached 80% confluency, FKA with a concentration of 40&#xa0;&#x3bc;M was administered alone or in combination with IL-1&#x3b2; (5&#xa0;ng/ml). Cells were incubated for 24&#xa0;h and washed with PBS. Cells were then fixed with 4% paraformaldehyde, and after discarding the cell fixative, they were stained with 0.5% Safranin O reagent for 2&#xa0;h. The dye was finally removed and washed once again with distilled water.</p>
</sec>
<sec id="s2-6">
<title>Western blot</title>
<p>The protein extraction was performed by first washing the mouse chondrocytes seeded in a 6-well plate using PBS thrice, followed by the addition of 100&#xa0;&#x3bc;l RIPA lysate buffer, 1&#xa0;&#x3bc;l phosphatase inhibitor, and protease inhibitor to each well. Additionally, the protein concentration was measured by employing the Bicinchoninic Acid Assay. Moreover, 25&#xa0;&#x3bc;g of protein samples were added to each well in the SDS-PAGE gel (8.0&#x2013;12.5%) for electrophoresis. The electroblotting method was employed for the separation of protein bands and transferring onto a polyvinylidene membrane, and blocking of the membrane was performed at room temperature using BSA (5%) for a period of 1&#xa0;h, and overnight incubation of the target band was carried out in the corresponding primary antibody at a temperature of 4&#xb0;C. Washing of the membrane was conducted in TBST three times, and a second incubation was performed in the corresponding secondary antibody for a period of 1&#xa0;h, then rinsed thrice with TBST again. The Image Lab software (Bio-Rad) was used to obtain clear western blotting bands.</p>
</sec>
<sec id="s2-7">
<title>Immunofluorescence</title>
<p>Laser confocal culture dish (34.8&#xa0;mm diameter) was utilized to seed the chondrocyte cells at a density of 1 &#xd7; 10<sup>4</sup> cells/well. 5&#xa0;ng/ml of IL-1&#x3b2; was added for treating the cells for 24&#xa0;h in the absence or presence of 40&#xa0;&#xb5;M FKA. Furthermore, PBS was utilized for washing (three times); cell fixation was carried out using 4% paraformaldehyde for a period of 15 min; cell permeabilization was performed by employing 0.5% Triton X-100 for a period of 15 min, and 5% BSA was employed for blocking. Overnight incubation of the chondrocytes was done with primary antibody against MMP13 (18165-1-AP, 1:50) and Aggrecan (ab36861, 1:100) at 4&#xb0;C. After that, they were rinsed using PBS three times, and incubation was performed again with fluorescent secondary antibodies (ab150083, 1:200) for a period of 60&#xa0;min. In addition, 0.5&#xa0;&#x3bc;g/ml DAPI was utilized for the nuclei staining. The cell imaging was carried out with the aid of a confocal microscopy (Leica, United States).</p>
</sec>
<sec id="s2-8">
<title>Senescence &#x3b2;-galactosidase staining</title>
<p>The senescent &#x3b2;-galactosidase staining was utilized to check the degree of cellular senescence. The washing of cells was conducted using PBS, and fixation was carried out for 15&#xa0;min. After that, the staining solution was added for overnight incubation at 37&#xb0;C in the absence of carbon dioxide. A microscope was employed for the observation and recording of the number of blue spots in the field of view.</p>
</sec>
<sec id="s2-9">
<title>Flow cytometry analysis</title>
<p>Chondrocytes were collected using 0.1% trypsin following the instructions provided by the manufacturer; PBS was used for washing (twice), and cell resuspension was performed in a binding buffer. Apoptotic cells were assessed by flow cytometry (Beckman Coulter, Inc. United States) after performing staining using propidium iodide and Annexin V (<xref ref-type="bibr" rid="B33">Sun et al., 2021</xref>).</p>
</sec>
<sec id="s2-10">
<title>Detection of autophagic flux</title>
<p>RFP-GFP-LC3-adenovirus was employed for the detection of autophagic flux. When the cells reached about 50% confluency, the cells were infected with adenovirus vectors for a day. Then use IL-1&#x3b2; (5&#xa0;ng/ml) pretreated cells in the presence or absence of FKA (40&#xa0;&#x3bc;M) for 24&#xa0;h. Due to acid sensitivity, green fluorescence is extinguished after autolysosome formation, and only red fluorescence can be detected (<xref ref-type="bibr" rid="B29">Pei et al., 2021</xref>). The number of autophagosomes and autolysosomes was then observed by confocal microscopy (Leica, United States).</p>
</sec>
<sec id="s2-11">
<title>Bioinformatics analysis of FKA</title>
<p>Through the PharmMapper and miRWalk2.0 databases, the FKA and OA-related pathways were identified, respectively. The prediction of FKA-target genes was performed based on the PharmMapper database, which was subsequently imported into the Database for Annotation, Visualization, and Integrated Discovery (DAVID) to carry out the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Moreover, in order to obtain FKA-related OA pathways, the incorporation of the KEGG pathways was conducted with OA-related pathways acquired using the miRWalk 2.0 database. Additionally, the Venn diagram (Venny2.1, <ext-link ext-link-type="uri" xlink:href="http://bioinfogp.cnb.csic.es/tools/venny/index.html">http://bioinfogp.cnb.csic.es/tools/venny/index.html</ext-link>) was utilized for the visualization of various intersected pathways related to FKA. Furthermore, Cytoscape 3.8.2 was employed for the screening of hub genes based on the degree, betweenness, and closeness centrality of FKA-target genes. The Pathway Builder Tool 2.0 (<ext-link ext-link-type="uri" xlink:href="https://www.proteinlounge.com/">https://www.proteinlounge.com</ext-link>) was employed to conduct KEGG pathway enrichment analysis, and the leading KEGG pathways were selected from the crossover pathways. Finally, the proximity of FKA-target genes in the network were illustrated by constructing a circos plot with the aid of the circlize R package, which also included the location of the genes on the chromosome and their connections.</p>
</sec>
<sec id="s2-12">
<title>DMM OA model</title>
<p>Eighteen specific pathogen-free C57BL/6J male mice were acquired from the Experimental Animal Center of Tongji Hospital. Mouse DMM OA model was established as previously described (<xref ref-type="bibr" rid="B24">Lu et al., 2021</xref>). The mouse were anesthetized by intraperitoneal injection of pentobarbital (100&#xa0;&#x3bc;l/10g body weight). Right knee surgery of all the mice was carried out and randomly classified into 3 groups. FKA group mice (<italic>n</italic> &#x3d; 6) underwent DMM surgery and were intra-articularly injected with 50&#xa0;mg/kg FKA weekly. Sham-operated group mice (<italic>n</italic> &#x3d; 6) underwent sham surgery (capsulotomy and suturing) and were injected with saline (equal volume). OA group mice (<italic>n</italic> &#x3d; 6) underwent DMM surgery and were injected intra-articularly with saline (equal volume). After Eight weeks of surgery, all mice were sacrificed with overdose anesthetics, and sample collection and fixation were performed using 4% paraformaldehyde for 24&#xa0;h.</p>
</sec>
<sec id="s2-13">
<title>Histological evaluation</title>
<p>Decalcification of the fixed samples was performed for 30&#xa0;days using the EDTA-Decalcifying-fluid, and 5-&#x3bc;m-thick fragments of the right knee joint were cut. In addition, hematoxylin and eosin (H&#x26;E), safranin-o-fast green as well as toluidine blue were used for the staining of these fragments (<xref ref-type="bibr" rid="B27">Pan et al., 2022</xref>). The expression of Aggrecan and Col2 in mouse cartilage was assessed by immunohistochemistry. The assessment of the changes in mouse articular cartilage was carried out as per the Osteoarthritis Research Society International (OARSI) scoring system (<xref ref-type="bibr" rid="B12">Glasson et al., 2010</xref>). Scoring was done by two independent investigators who have no knowledge of the grouping.</p>
</sec>
<sec id="s2-14">
<title>Micro-computed tomography</title>
<p>We used a small animal micro-CT (Scanco Medical AG, Bassersdorf, Switzerland) for the purpose of scanning the right knee joint of the mice. After obtaining the image, the internal software of the microCT system was used for 3D reconstruction. Statistical analysis was then performed using the trabecular numbers (Tb.N), trabecular separation (Tb.Sp), and bone volume/tissue volume (BV/TV) of the samples.</p>
</sec>
<sec id="s2-15">
<title>Statistical analysis</title>
<p>Independent repetition of each experiment was conducted at least thrice, and analysis of data was carried out by employing the GraphPad prism V.8 software (GraphPad Inc., La Jolla, CA, United States). Additionally, all the data were represented by mean &#x2b;standard deviation (SD), and relevant analyses were conducted using one-way analysis of variance (ANOVA) followed by Turkey&#x2019;s post-hoc test. Statistical significance was determined by <italic>p</italic> &#x2264; 0.05.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Effect of FKA on cell viability</title>
<p>We used the CCK 8 kit to determine the impact of various concentrations of FKA on the viability of chondrocytes. The molecular structure of FKA can be seen in <xref ref-type="fig" rid="F1">Figure 1A</xref>. The illustrations in <xref ref-type="fig" rid="F1">Figures 1C,D</xref> reveal that the presence or absence of IL-1&#x3b2; (5&#xa0;ng/ml) and different concentrations of FKA had no effect on cell viability. Based on current and previous findings (<xref ref-type="bibr" rid="B20">Kwon et al., 2013</xref>), we used 20&#xa0;&#x3bc;M and 40&#xa0;&#x3bc;M of FKA for subsequent experiments. In addition, Safranin O staining showed that the morphology of chondrocytes did not change after FKA intervention (<xref ref-type="fig" rid="F1">Figure 1B</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Effects of FKA on chondrocyte viability <bold>(A)</bold> Chemical Structure of FKA. <bold>(B)</bold> Safranin O staining of chondrocyte cells after treatment with IL-1&#x3b2; (5&#xa0;ng/ml) and FKA for a period of 24&#xa0;h (scale bar 100&#xa0;&#x3bc;m). Viability of chondrocyte cells after 24&#xa0;h intervention with various concentrations of FKA in the absence <bold>(C)</bold> or presence of IL-1&#x3b2; <bold>(D)</bold> tested using the CCK8 kit. The values are presented as means &#xb1; SD (<italic>n</italic> &#x3d; 3).</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g001.tif"/>
</fig>
</sec>
<sec id="s3-2">
<title>FKA inhibits chondrocyte inflammation and catabolism induced by IL-1&#x3b2;</title>
<p>The western blot was utilized to assess the impact of FKA on cartilage inflammation and metabolism. <xref ref-type="fig" rid="F2">Figure 2(A&#x2013;D)</xref> illustrates that IL-1&#x3b2; elevated the expression levels of chondrocyte inflammatory cytokines (COX2 and iNOS), MMPs (MMP3/13), and ADAMTS5, whereas FKA lowered their expression levels in a concentration-dependent manner. Additionally, FKA also reversed the impacts of IL-1&#x3b2; on the anabolism of chondrocytes. The expression of Col2, Aggrecan, and Sox9 in chondrocytes showed a significant downward trend under the influence of IL-1&#x3b2;, but the effect was reversed under the effect of FKA (<xref ref-type="fig" rid="F2">Figures 2E,F</xref>). The results of immunofluorescence were consistent with the western blot data (<xref ref-type="fig" rid="F2">Figures 2G&#x2013;I</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Protective effects of FKA against IL-1&#x3b2;-induced inflammation and ECM destruction in mouse chondrocytes. Chondrocyte cell treatment with 5&#xa0;ng/ml of IL-1&#x3b2; only or with FKA (20 and 40&#xa0;&#x3bc;M) for a period of 24&#xa0;h. Western blot analysis of inflammatory cytokines (COX2 and iNOS), catabolic (ADAMTS5, MMP3, and MMP13), and anabolic markers (Col2, Aggrecan, and Sox9) <bold>(A,C and E)</bold>. Quantitative analysis of protein expression <bold>(B,D and F)</bold>. <bold>(G and H)</bold> 5&#xa0;ng/ml of IL-1&#x3b2; was added for treating the cells for 24&#xa0;h in the absence or presence of 40&#xa0;&#xb5;M FKA. Confocal microscopy showing the expression of MMP13 and Aggrecan in immunofluorescence experiments (scale bar 10&#xa0;&#x3bc;m). <bold>(I)</bold> Relative quantification of fluorescence intensity. The values are presented as means &#xb1; SD (<italic>n</italic> &#x3d; 3). &#x23;<italic>p</italic> &#x3c; 0.05 vs the control group; &#x2a;<italic>p</italic> &#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 vs the IL-1&#x3b2; group.</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>FKA regulates the expression of senescence-related genes in chondrocytes</title>
<p>The chondrocyte cells during OA exhibited elevated levels of various senescence markers, for instance, &#x3b2;-galactosidase, as well as the increased expression of senescence-related genes (<xref ref-type="bibr" rid="B25">McCulloch et al., 2017</xref>). <xref ref-type="fig" rid="F3">Figures 3A,B</xref> show that the levels of expression of P16 and P21 proteins were elevated in chondrocytes under the influence of IL-1&#x3b2;, whereas FKA suppressed their expression. Additionally, the senescence &#x3b2;-galactosidase staining kit was employed to test the &#x3b2;-galactosidase activity in different groups. Under elevated IL-1&#x3b2; levels, the activity of &#x3b2;-galactosidase was increased (more blue spots), and FKA decreased its activity (<xref ref-type="fig" rid="F3">Figures 3C,D</xref>).</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>The regulation of FKA on the expression of senescence-related genes in chondrocytes <bold>(A)</bold> Western blot analysis revealing P16 and P21 expression in chondrocytes. <bold>(B)</bold> Quantitative analysis of protein expression <bold>(C)</bold>. &#x3b2;-Galactosidase used for the staining of chondrocyte cells (scale bar 100&#xa0;&#x3bc;m) <bold>(D)</bold> Quantitative analysis of &#x3b2;-galactosidase expression. The values are presented as means &#xb1; SD (<italic>n</italic> &#x3d; 3). &#x23;<italic>p</italic> &#x3c; 0.05 vs control group; &#x2a;<italic>p</italic> &#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 vs IL-1&#x3b2; group. </p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g003.tif"/>
</fig>
</sec>
<sec id="s3-4">
<title>FKA suppresses IL-1&#x3b2;-induced apoptosis in mouse chondrocytes</title>
<p>Chondrocyte apoptosis has a close correlation with the severity of cartilage damage in OA. In the current study, we treated chondrocytes with FKA in the IL-1&#x3b2; presence or absence for a period of 24&#xa0;h. <xref ref-type="fig" rid="F4">Figures 4A,B</xref> indicate that treatment with IL-1&#x3b2; markedly upregulated Bax and downregulated Bcl2 expression in chondrocytes. However, FKA alleviated these trends. In order to determine the apoptosis status of chondrocytes, we employed the Annexin V-FITC/PI Apoptosis Detection kit. <xref ref-type="fig" rid="F4">Figures 4C,D</xref> illustrate that FKA treatment led to a remarkable decrease in IL-1&#x3b2;-induced apoptosis of chondrocytes.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Impacts of FKA on IL-1&#x3b2;-induced apoptosis in mouse chondrocytes <bold>(A)</bold> Western blot findings revealing Bax and Bcl2 expression in chondrocytes. <bold>(B)</bold> Quantitative analysis of protein expression. <bold>(C)</bold> The apoptosis rate of chondrocyte cells was detected by flow cytometry. <bold>(D)</bold> The apoptosis rate of chondrocyte cells in all groups were detected with Annexin V-FITC/PI staining and flow cytometry. The values are presented as means &#xb1; SD (n &#x3d; 3). &#x23;<italic>p</italic> &#x3c; 0.05 vs control group; &#x2a;<italic>p</italic> &#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 vs IL-1&#x3b2; group.</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g004.tif"/>
</fig>
</sec>
<sec id="s3-5">
<title>FKA regulates IL-1&#x3b2;-induced suppression of the expression of autophagy-related genes in chondrocytes</title>
<p>Numerous pieces of evidence indicate that a crucial role is played by autophagy in the progression of OA (<xref ref-type="bibr" rid="B26">Musumeci et al., 2015</xref>; <xref ref-type="bibr" rid="B23">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="B36">Yan et al., 2022</xref>). Therefore, we analyzed the impacts of FKA on autophagy in IL-1&#x3b2;-treated mouse chondrocyte cells. <xref ref-type="fig" rid="F5">Figures 5A,B</xref> reveal that IL-1&#x3b2; treatment remarkably suppressed the ATG12, LC3&#x2161;/LC3, and Beclin, expression levels in mouse chondrocytes. However, the administration of 40&#xa0;&#x3bc;M FKA significantly reversed these changes. Moreover, RFP-GFP-LC3-adenovirus was employed to further verify the impact of FKA on autophagy. We observed that the number of autophagolysosomes and autophagosomes decreased in chondrocyte cells treated with IL-1&#x3b2;, and FKA pretreatment reversed this trend as illustrated in <xref ref-type="fig" rid="F5">Figure 5E</xref>. Furthermore, the autophagy inhibitor, 3MA, attenuated the promoting effect of FKA on IL-1&#x3b2;-induced chondrocyte autophagy (<xref ref-type="fig" rid="F5">Figures 5C,D</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>FKA regulates IL-1&#x3b2;-induced autophagy-related gene expression in chondrocytes <bold>(A)</bold> Western blot results show Beclin, ATG12, and LC3I/LC3II expression in chondrocytes. <bold>(B)</bold> Quantitative analysis of protein expression. <bold>(C)</bold> Effect of FKA on autophagy in chondrocytes after treatment with the autophagy inhibitor 3&#xa0;MA. <bold>(D)</bold> Quantitative analysis of protein expression. <bold>(E)</bold> After 5&#xa0;ng/ml of IL-1&#x3b2; was added for treating the cells for 24&#xa0;h in the absence or presence of 40&#xa0;&#xb5;M FKA, detection of autophagy in chondrocytes transfected with RFP-GFP-LC3-adenovirus was performed (scale bar 25&#xa0;&#x3bc;m). Autophagosomes denoted by the green dots, autophagolysosomes denoted by the red dots. The values are presented as means &#xb1; SD (<italic>n</italic> &#x3d; 3). &#x23;<italic>p</italic> &#x3c; 0.05 vs control group; &#x2a;<italic>p</italic> &#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 vs IL-1&#x3b2; group.</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g005.tif"/>
</fig>
</sec>
<sec id="s3-6">
<title>FKA alters antioxidant gene expression in chondrocytes</title>
<p>A crucial role is exerted by oxidative stress in the advancement of OA (<xref ref-type="bibr" rid="B11">Feng et al., 2019</xref>). According to a previous study, FKA alters the expression of antioxidant genes in primary splenocytes (<xref ref-type="bibr" rid="B37">Yang et al., 2020</xref>). Therefore, we assessed whether FKA could alter the IL-1&#x3b2;-induced expression of antioxidant genes, including NQO1, Nrf2, and HO-1 in chondrocytes. The results in <xref ref-type="fig" rid="F6">Figures 6A,B</xref> illustrate that FKA substantially increased the expression of antioxidant genes in chondrocytes.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>FKA alters antioxidant gene expression in chondrocytes <bold>(A)</bold> Western blot assay revealing Nrf2, HO-1, and NQO1 expression in chondrocytes. <bold>(B)</bold> Quantitative analysis of protein expression. The values are presented as means &#xb1; SD (n &#x3d; 3). &#x23;<italic>p</italic> &#x3c; 0.05 vs control group; &#x2a;<italic>p</italic> &#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 vs IL-1&#x3b2; group.</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="s4">
<title>Results of bioinformatics analysis of FKA</title>
<p>The identification of potential FKA-target genes was performed using the PharmMapper database. The KEGG pathway enrichment analysis revealed the enrichment of FKA -target genes in 155 pathways. The four leading pathways identified with the most enriched genes were PI3K/Akt, proteoglycans in cancer, prostate cancer, and MAPK signaling pathways (<xref ref-type="fig" rid="F7">Figure 7A</xref>). In addition, 105 OA-related pathways were identified based on the mirWalk2.0 database. We identified 45 common pathways related to FKA and OA (<xref ref-type="fig" rid="F7">Figure 7B</xref>). Information on the six KEGG pathways with the most enriched genes, including the PI3K/Akt, MAPK signaling pathway, proteoglycans in cancer, Chemical carcinogenesis -receptor activation, Chemical carcinogenesis -reactive oxygen species, and Lipid and atherosclerosis is presented in <xref ref-type="fig" rid="F7">Figure 7C</xref>. <xref ref-type="fig" rid="F7">Figure 7D</xref> illustrates the circular diagram revealing the FKA-target genes&#x2019; chromosomal position and connectivity. Moreover, the AKT1 gene also illustrates a superior closeness, degree, and betweenness centrality.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Bioinformatics analysis of FKA pathways and target genes <bold>(A)</bold> KEGG pathway enrichment analysis of FKA target genes. <bold>(B)</bold> The intersection between FKA-related KEGG pathways and OA-related pathways. <bold>(C)</bold> Top six paths in cross paths (KEGG enriched chord diagram). <bold>(D)</bold> Assessment of Centrality and chromosomal investigation of FKA-related central genes.</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g007.tif"/>
</fig>
<sec id="s4-1">
<title>Effect of FKA on the PI3K/Akt/mTOR and MAPK pathways induced by IL-1&#x3b2; in mouse chondrocytes</title>
<p>The PI3K/Akt/mTOR and MAPK pathways exert a significant function in the autophagy, inflammation, and progression of OA (<xref ref-type="bibr" rid="B28">Park et al., 2018</xref>). In this study, treatment of chondrocyte cells was performed with IL-1&#x3b2; only or in combination with 20&#xa0;&#x3bc;M or 40&#xa0;&#x3bc;M FKA for 30&#xa0;min, and protein expression in chondrocytes was assessed using the western blot technique. As shown in (<xref ref-type="fig" rid="F8">Figure 8</xref>), FKA pretreatment partially inhibited IL-1&#x3b2;-stimulated phosphorylation of the genes involved in the MAPK and PI3K pathways.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Effect of FKA on the PI3K/Akt/mTOR pathway and MAPK pathway induced by IL-1&#x3b2; in mouse chondrocyte cells <bold>(A)</bold> The expression of proteins of the MAPK pathway illustrated by western blot analysis. <bold>(B)</bold> Quantitative analysis of protein expression. <bold>(C)</bold> Western blot results show the expression of proteins of the PI3K/Akt/mTOR pathway. <bold>(D)</bold> Quantitative analysis of protein expression. The values are presented as means &#xb1; SD (<italic>n</italic> &#x3d; 3). &#x23;<italic>p</italic> &#x3c; 0.05 vs control group; &#x2a;<italic>p</italic> &#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 vs IL-1&#x3b2; group.</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g008.tif"/>
</fig>
</sec>
<sec id="s4-2">
<title>Effects of FKA on mouse OA model</title>
<p>Furthermore, the effects of FKA on OA onset and progression were detected in the mouse models. The histological analysis revealed remarkably less cartilage damage in the FKA group in comparison to the OA model group (<xref ref-type="fig" rid="F9">Figures 9A,B</xref>). Moreover, immunohistochemical results revealed that the FKA group showed significantly increased expression of Aggrecan and Col2 in comparison to the OA model group (<xref ref-type="fig" rid="F9">Figures 9C&#x2013;E</xref>).</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Impacts of FKA on mouse OA model <bold>(A)</bold> H&#x26;E, safranin, and toluidine blue staining of cartilage in the mouse OA model. <bold>(B)</bold> Osteoarthritis Research Society International (OARSI) scoring system <bold>(C)</bold> Immunohistochemistry staining of the expression of Aggrecan and Col2 were conducted on three groups of cartilage tissues (scale bars, 50 and 100&#xa0;&#x3bc;m). <bold>(D and E)</bold> Quantitative analysis of immunohistochemistry. The values are presented as means &#xb1; SD (<italic>n</italic> &#x3d; 6). &#x23;<italic>p</italic> &#x3c; 0.05 vs sham group; &#x2a;<italic>p</italic> &#x3c; 0.05 vs OA group.</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g009.tif"/>
</fig>
</sec>
<sec id="s4-3">
<title>Micro-CT evaluation of the effect of FKA on subchondral bone remodeling in mouse OA model</title>
<p>A micro-CT was conducted for the evaluation of the impact of FKA on subchondral bone remodeling in the OA models. In <xref ref-type="fig" rid="F10">Figure 10</xref>, we can observe that the bone volume fraction (BV/TV) and the trabecular number (Tb.N) in the OA model group were evidently increased in comparison to the sham group, and the degree of trabecular separation (Tb.Sp) was significantly reduced. However, after FKA treatment, these trends were significantly reversed. These findings suggest that FKA had a promising amelioration impact on subchondral bone remodeling in OA mice.</p>
<fig id="F10" position="float">
<label>FIGURE 10</label>
<caption>
<p>Micro-CT evaluation of the impact of FKA on subchondral bone remodeling in the mouse OA model. <bold>(A)</bold> 3D image of mouse OA model generated by micro-CT scan. <bold>(B)</bold> Coronal image views of the right knee from the sham, OA, and OA&#x2b; FKA group mice. <bold>(C)</bold> BV/TV, Tb.N, and Tb. Sp of the three groups. &#x2a;<italic>p</italic> &#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.01 vs sham group (scale bar 1&#xa0;mm).</p>
</caption>
<graphic xlink:href="fbioe-10-1071776-g010.tif"/>
</fig>
</sec>
</sec>
<sec sec-type="discussion" id="s5">
<title>Discussion</title>
<p>As the existing treatments are unsatisfactory, osteoarthritis will undoubtedly continue to deteriorate the quality of life of the elderly. In recent years, natural plant extracts have attracted a lot of attention in the treatment of diseases (<xref ref-type="bibr" rid="B32">Robinson et al., 2016</xref>). FKA, a chalcone from <italic>Piper methysticum</italic> Forst extract, has been reported to have multiple biological activities. In the research conducted by our group, we reported FKA&#x2019;s therapeutic effects in a mouse model of OA and its underlying mechanism of action. Local inflammatory responses are crucial in the development of OA as they induce the secretion of inflammatory mediators, i.e., TNF&#x3b1; and IL-1&#x3b2; (<xref ref-type="bibr" rid="B9">Dumond et al., 2004</xref>). For the activation of different inflammatory pathways, for instance, the PI3K/Akt and MAPK pathways, IL-1&#x3b2; plays a crucial role. Several studies have shown that inhibition of these pathways can contribute to the reduction of inflammation and matrix-degrading enzymes, and to the improvement of cartilage degeneration in the long run (<xref ref-type="bibr" rid="B22">Lianxu et al., 2006</xref>; <xref ref-type="bibr" rid="B14">Herrero-Beaumont et al., 2019</xref>). We observed that the inflammatory factors such as COX2 and iNOS and catabolic factors, like ADAMTS5, MMP3, and MMP13 significantly increased after IL-1&#x3b2; intervention in chondrocytes, but anabolic enzymes, for instance, Col2, Aggrecan, and SOX9 were significantly reduced. These trends have been reversed with the addition of FKA in a dose dependent manner. Cellular senescence is also an important part of OA progression. Senescent cells in joint tissues are thought to be responsible for the development of OA (<xref ref-type="bibr" rid="B8">Coryell et al., 2021</xref>). Our study shows that FKA can substantially suppress the expression of P16 and P21<italic>,</italic> senescence cell-related genes, in chondrocytes induced by IL-1&#x3b2;. OA is also characterized by enhanced apoptosis in chondrocytes (<xref ref-type="bibr" rid="B16">Hwang and Kim, 2015</xref>). Therefore, reducing the apoptosis rate of chondrocytes is a potential treatment strategy for OA. We found that the rate of IL-1&#x3b2;-induced apoptosis can be attenuated by FKA in chondrocyte cells. <xref ref-type="bibr" rid="B4">Barranco, (2015)</xref> found that the AKT-mTOR signaling pathway directly mediates autophagy in chondrocyte cells. The onset and progression of OA mediated by excessive production of reactive oxygen species (ROS) are countered by autophagy (<xref ref-type="bibr" rid="B6">Charlier et al., 2016</xref>). Autophagy decreases cellular ROS, resulting in the protection of chondrocytes. Therefore, a significant role is played by autophagy in the protection of chondrocyte cells from oxidative stress (<xref ref-type="bibr" rid="B2">Ansari et al., 2018</xref>). Furthermore, the Nrf2/HO-1 signaling pathway contributes to the resistance to oxidative stress, and its activation can promote the expression of multiple antioxidant factors downstream. In our study, it was confirmed that FKA could partially reverse IL-1&#x3b2;-induced downregulation of autophagy. The protective impact of FKA on IL-1&#x3b2;-induced chondrocyte cells was reduced under the influence of 3MA, an autophagy inhibitor. Moreover, FKA also promoted the Nrf2/HO-1 signaling pathway expression. Therefore, FKA protects against oxidative stress by promoting autophagy and activating anti-oxidative pathways. As a result of bioinformatic analysis, we identified AKT1 as a potential target of FKA. Previous study confirmed that miR-495 induced chondrocyte apoptosis and senescence <italic>via</italic> directly targeting AKT1 and regulating the AKT/mTOR signaling pathway (<xref ref-type="bibr" rid="B38">Zhao et al., 2019</xref>). It may be possible in future studies to determine whether FKA acts as an anti-arthritis agent by targeting AKT1. Also, bioinformatic analysis suggested that the PI3K/AKT pathway and MAPK pathway could be two potential mechanisms of FKA involved in the occurrence and progression of OA. These mechanisms are directly linked to the onset and progression of OA (<xref ref-type="bibr" rid="B35">Wu et al., 2021</xref>), as well as closely related to autophagy. It has been demonstrated in previous studies that the PI3K/AKT/mTOR and MAPK pathways inhibition can reduce the inflammatory response in OA (<xref ref-type="bibr" rid="B39">Zhou et al., 2019</xref>). Our results show that FKA can protect chondrocytes by inhibiting the phosphorylation of the genes involved in PI3K/AKT/mTOR and MAPK pathways induced by IL-1&#x3b2;. In order to validate the therapeutic effects of FKA, we performed <italic>in vivo</italic> experiments. As expected, FKA alleviated the OA progression in a mouse OA model.</p>
<p>In summary, these results emphasize FKA&#x2019;s potential as a reliable drug for treating OA. However, there are some limitations to this study. Firstly, detrimental concentrations of FKA on chondrocytes were not validated. In addition, the possible effects of FKA on other organs (liver and kidney, <italic>etc.</italic>) were not investigated. In comparison with systemic drug delivery, intraarticular delivery offers numerous advantages, including the increase in local bioavailability, the reduction of adverse events, and the lower cost (<xref ref-type="bibr" rid="B10">Emami et al., 2018</xref>). In spite of this, intraarticular therapies remain controversial in terms of their efficacy. The drug residence time in the joint is largely determined by the size of the molecule (<xref ref-type="bibr" rid="B17">Jones et al., 2019</xref>). The drug residence time of FKA in the articular cavity has not been studied in this study, which is another limitation. Moreover, ineffectiveness of systemic delivery and low bioavailability of natural plant extracts are also factors that have not yet been translated into clinical applications. During the past decade, remarkable progress has been made in the development of novel drug delivery systems (nanoparticles) for encapsulating plant active metabolites. Hence, combining FKA and novel nanocarriers may be the key to making it applicable in clinical settings, which can be explored in further studies (<xref ref-type="bibr" rid="B5">Bharali et al., 2011</xref>; <xref ref-type="bibr" rid="B30">Rahman et al., 2020</xref>).</p>
</sec>
<sec sec-type="conclusion" id="s6">
<title>Conclusion</title>
<p>In conclusion, this report is the first to observe that FKA can protect chondrocytes by inhibiting the MAPK and PI3K pathways. FKA can promote the autophagy of chondrocytes and improve their antioxidant capacity. Our findings offer insights into developing novel treatment strategies for OA.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s7">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s8">
<title>Ethics statement</title>
<p>The animal study was reviewed and approved by Animal Care and Use Committee for Teaching and Research, Tongji Medical College, Huazhong University of Science and Technology.</p>
</sec>
<sec id="s9">
<title>Author contributions</title>
<p>SJ and WL worked on conception and design. <italic>In vitro</italic> and <italic>in vivo</italic> experiments were conducted by SJ and JW. Data collection was conducted by SJ, JW, TW, ZH, QD, GS, SW, HZ, and ZZ. JW, SW, and HW carried out the data analysis. The manuscript was drafted by SJ and JW. Funding for the study was provided by WL and HW. The final version of the manuscript has been approved by all authors.</p>
</sec>
<sec id="s10">
<title>Funding</title>
<p>This work was financially supported by the National Natural Science Foundation for Young Scientists of China (Grant No. 51807078) to WL and the National Natural Science Foundation of China (Grant No.51537004) to HW.</p>
</sec>
<ack>
<p>We thank Bullet Edits Limited for editing and proofreading the manuscript for language proficiency.</p>
</ack>
<sec sec-type="COI-statement" id="s11">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s12">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s13">
<title>Abbreviations</title>
<p>FKA, Flavokawain A; OA, osteoarthritis; COX2, cyclooxygenase-2; IL-1&#x3b2;, interleukin-1 beta; iNOS, inducible nitric oxide synthase; MMPs, matrix metalloproteinases; SOX9, sry-box transcription factor 9; CCK-8, cell counting kit-8; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; PI3K/AKT/mTOR, phosphoinositide-3-kinase/Akt/mammalian target of rapamycin; HE, hematoxylin and eosin; OARSI, Osteoarthritis Research Society International; Nrf2, Nuclear factor erythroid 2-related factor 2; HO-1, Heme Oxygenase-1 Antibody; NQO1, NAD(P)H:quinone oxidoreductase 1.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aicher</surname>
<given-names>W. K.</given-names>
</name>
<name>
<surname>Rolauffs</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The spatial organisation of joint surface chondrocytes: Review of its potential roles in tissue functioning, disease and early, preclinical diagnosis of osteoarthritis</article-title>. <source>Ann. Rheum. Dis.</source> <volume>73</volume> (<issue>4</issue>), <fpage>645</fpage>&#x2013;<lpage>653</lpage>. <pub-id pub-id-type="doi">10.1136/annrheumdis-2013-204308</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ansari</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>N. M.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Haqqi</surname>
<given-names>T. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Parkin clearance of dysfunctional mitochondria regulates ROS levels and increases survival of human chondrocytes</article-title>. <source>Osteoarthr. Cartil.</source> <volume>26</volume> (<issue>8</issue>), <fpage>1087</fpage>&#x2013;<lpage>1097</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2017.07.020</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Appleton</surname>
<given-names>C. T.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Osteoarthritis year in review 2017: Biology</article-title>. <source>Osteoarthr. Cartil.</source> <volume>26</volume> (<issue>3</issue>), <fpage>296</fpage>&#x2013;<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2017.10.008</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barranco</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Osteoarthritis: Activate autophagy to prevent cartilage degeneration?</article-title> <source>Nat. Rev. Rheumatol.</source> <volume>11</volume> (<issue>3</issue>), <fpage>127</fpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2015.12</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bharali</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Adhami</surname>
<given-names>V. M.</given-names>
</name>
<name>
<surname>Chamcheu</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Aldahmash</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Mukhtar</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Nanoparticle delivery of natural products in the prevention and treatment of cancers: Current status and future prospects</article-title>. <source>Cancers (Basel)</source> <volume>3</volume> (<issue>4</issue>), <fpage>4024</fpage>&#x2013;<lpage>4045</lpage>. <pub-id pub-id-type="doi">10.3390/cancers3044024</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charlier</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Relic</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Deroyer</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Malaise</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Neuville</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Coll&#xe9;e</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Insights on molecular mechanisms of chondrocytes death in osteoarthritis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>17</volume> (<issue>12</issue>), <fpage>2146</fpage>. <pub-id pub-id-type="doi">10.3390/ijms17122146</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S. C.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Resistin enhances IL-1&#x3b2; and TNF-&#x3b1; expression in human osteoarthritis synovial fibroblasts by inhibiting miR-149 expression via the MEK and ERK pathways</article-title>. <source>FASEB J.</source> <volume>34</volume> (<issue>10</issue>), <fpage>13671</fpage>&#x2013;<lpage>13684</lpage>. <pub-id pub-id-type="doi">10.1096/fj.202001071R</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coryell</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Diekman</surname>
<given-names>B. O.</given-names>
</name>
<name>
<surname>Loeser</surname>
<given-names>R. F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Mechanisms and therapeutic implications of cellular senescence in osteoarthritis</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>17</volume> (<issue>1</issue>), <fpage>47</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-020-00533-7</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumond</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Presle</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pottie</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pacquelet</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Terlain</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Netter</surname>
<given-names>P.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Site specific changes in gene expression and cartilage metabolism during early experimental osteoarthritis</article-title>. <source>Osteoarthr. Cartil.</source> <volume>12</volume> (<issue>4</issue>), <fpage>284</fpage>&#x2013;<lpage>295</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2003.11.008</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emami</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Short</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yaksh</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Bendele</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Ramani</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Toxicology evaluation of drugs administered via uncommon routes: Intranasal, intraocular, intrathecal/intraspinal, and intra-articular</article-title>. <source>Int. J. Toxicol.</source> <volume>37</volume> (<issue>1</issue>), <fpage>4</fpage>&#x2013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1177/1091581817741840</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Curcumin inhibits the PERK-eIF2&#x3b1;-CHOP pathway through promoting SIRT1 expression in oxidative stress-induced rat chondrocytes and ameliorates osteoarthritis progression in a rat model</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2019</volume>, <fpage>1</fpage>&#x2013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1155/2019/8574386</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glasson</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Chambers</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Van Den Berg</surname>
<given-names>W. B.</given-names>
</name>
<name>
<surname>Little</surname>
<given-names>C. B.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse</article-title>. <source>Osteoarthr. Cartil.</source> <volume>18</volume>, <fpage>S17</fpage>&#x2013;<lpage>S23</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2010.05.025</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glyn-Jones</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Agricola</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Weinans</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Osteoarthritis</article-title>. <source>Lancet</source> <volume>386</volume> (<issue>9991</issue>), <fpage>376</fpage>&#x2013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(14)60802-3</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrero-Beaumont</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>P&#xe9;rez-Baos</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>S&#xe1;nchez-Pernaute</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Roman-Blas</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Lamuedra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Largo</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Targeting chronic innate inflammatory pathways, the main road to prevention of osteoarthritis progression</article-title>. <source>Biochem. Pharmacol.</source> <volume>165</volume>, <fpage>24</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2019.02.030</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hseu</surname>
<given-names>Y. C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Rajendran</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mathew</surname>
<given-names>D. C.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>C. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Chalcone flavokawain A attenuates TGF-&#x3b2;1-induced fibrotic pathology via inhibition of ROS/Smad3 signaling pathways and induction of Nrf2/ARE-mediated antioxidant genes in vascular smooth muscle cells</article-title>. <source>J. Cell. Mol. Med.</source> <volume>23</volume> (<issue>2</issue>), <fpage>775</fpage>&#x2013;<lpage>788</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.13973</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hwang</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H. A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Chondrocyte apoptosis in the pathogenesis of osteoarthritis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>16</volume> (<issue>11</issue>), <fpage>26035</fpage>&#x2013;<lpage>26054</lpage>. <pub-id pub-id-type="doi">10.3390/ijms161125943</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>I. A.</given-names>
</name>
<name>
<surname>Togashi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>M. L.</given-names>
</name>
<name>
<surname>Heckmann</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vangsness</surname>
<given-names>C. T.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group> (<year>2019</year>). <article-title>Intra-articular treatment options for knee osteoarthritis</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>15</volume> (<issue>2</issue>), <fpage>77</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-018-0123-4</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katz</surname>
<given-names>J. N.</given-names>
</name>
<name>
<surname>Arant</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Loeser</surname>
<given-names>R. F.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Diagnosis and treatment of hip and knee osteoarthritis: A review</article-title>. <source>Jama</source> <volume>325</volume> (<issue>6</issue>), <fpage>568</fpage>&#x2013;<lpage>578</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.22171</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Squires</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Mousa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tanzer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zukor</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Antoniou</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>). <article-title>Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage</article-title>. <source>Arthritis Rheum.</source> <volume>52</volume> (<issue>1</issue>), <fpage>128</fpage>&#x2013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1002/art.20776</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Ju</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Youn</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Suppression of iNOS and COX-2 expression by flavokawain A via blockade of NF-&#x3ba;B and AP-1 activation in RAW 264.7 macrophages</article-title>. <source>Food Chem. Toxicol.</source> <volume>58</volume>, <fpage>479</fpage>&#x2013;<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2013.05.031</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Le Maitre</surname>
<given-names>C. L.</given-names>
</name>
<name>
<surname>Pockert</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Buttle</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Freemont</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Hoyland</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>Matrix synthesis and degradation in human intervertebral disc degeneration</article-title>. <source>Biochem. Soc. Trans.</source> <volume>35</volume>, <fpage>652</fpage>&#x2013;<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1042/bst0350652</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lianxu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hongti</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Changlong</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>NF-&#x3ba;Bp65-specific siRNA inhibits expression of genes of COX-2, NOS-2 and MMP-9 in rat IL-1&#x3b2;-induced and TNF-&#x3b1;-induced chondrocytes</article-title>. <source>Osteoarthr. Cartil.</source> <volume>14</volume> (<issue>4</issue>), <fpage>367</fpage>&#x2013;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1016/j.joca.2005.10.009</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qian</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Stimulation of &#x3b1;7-nAChRs coordinates autophagy and apoptosis signaling in experimental knee osteoarthritis</article-title>. <source>Cell Death Dis.</source> <volume>12</volume> (<issue>5</issue>), <fpage>448</fpage>. <pub-id pub-id-type="doi">10.1038/s41419-021-03726-4</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Z. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Physalin A inhibits MAPK and NF-&#x3ba;B signal transduction through integrin &#x3b1;V&#x3b2;3 and exerts chondroprotective effect</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>761922</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.761922</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCulloch</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Litherland</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Rai</surname>
<given-names>T. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Cellular senescence in osteoarthritis pathology</article-title>. <source>Aging Cell</source> <volume>16</volume> (<issue>2</issue>), <fpage>210</fpage>&#x2013;<lpage>218</lpage>. <pub-id pub-id-type="doi">10.1111/acel.12562</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Musumeci</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Castrogiovanni</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Trovato</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>Weinberg</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Al-Wasiyah</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Alqahtani</surname>
<given-names>M. H.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Biomarkers of chondrocyte apoptosis and autophagy in osteoarthritis</article-title>. <source>Int. J. Mol. Sci.</source> <volume>16</volume> (<issue>9</issue>), <fpage>20560</fpage>&#x2013;<lpage>20575</lpage>. <pub-id pub-id-type="doi">10.3390/ijms160920560</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Naringenin protects against iron overload-induced osteoarthritis by suppressing oxidative stress</article-title>. <source>Phytomedicine</source> <volume>105</volume>, <fpage>154330</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2022.154330</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Yim</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M. H.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Sargassum serratifolium extract attenuates interleukin-1&#x3b2;-induced oxidative stress and inflammatory response in chondrocytes by suppressing the activation of NF-&#x3ba;B, p38 MAPK, and PI3K/akt</article-title>. <source>Int. J. Mol. Sci.</source> <volume>19</volume> (<issue>8</issue>), <fpage>2308</fpage>. <pub-id pub-id-type="doi">10.3390/ijms19082308</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pei</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ni</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>You</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Selective STAT3 inhibitor alantolactone ameliorates osteoarthritis via regulating chondrocyte autophagy and cartilage homeostasis</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>730312</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.730312</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahman</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Othman</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Hammadi</surname>
<given-names>N. I.</given-names>
</name>
<name>
<surname>Yeap</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Abdul Samad</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>&#x3c;p&#x26;gt;Novel drug delivery systems for loading of natural plant extracts and their biomedical applications&#x3c;/p&#x26;gt;</article-title>. <source>Int. J. Nanomedicine</source> <volume>15</volume>, <fpage>2439</fpage>&#x2013;<lpage>2483</lpage>. <pub-id pub-id-type="doi">10.2147/ijn.S227805</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajendran</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Alzahrani</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Priya Veeraraghavan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>E. A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Anti-apoptotic effect of flavokawain A on ochratoxin-A-induced endothelial cell injury by attenuation of oxidative stress via PI3K/AKT-Mediated Nrf2 signaling cascade</article-title>. <source>Toxins (Basel)</source> <volume>13</volume> (<issue>11</issue>), <fpage>745</fpage>. <pub-id pub-id-type="doi">10.3390/toxins13110745</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robinson</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Lepus</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Raghu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lindstrom</surname>
<given-names>T. M.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis</article-title>. <source>Nat. Rev. Rheumatol.</source> <volume>12</volume> (<issue>10</issue>), <fpage>580</fpage>&#x2013;<lpage>592</lpage>. <pub-id pub-id-type="doi">10.1038/nrrheum.2016.136</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hyperoside ameliorates the progression of osteoarthritis: An <italic>in vitro</italic> and <italic>in vivo</italic> study</article-title>. <source>Phytomedicine</source> <volume>80</volume>, <fpage>153387</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2020.153387</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woolf</surname>
<given-names>A. D.</given-names>
</name>
<name>
<surname>Pfleger</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Burden of major musculoskeletal conditions</article-title>. <source>Bull. World Health Organ.</source> <volume>81</volume> (<issue>9</issue>), <fpage>646</fpage>&#x2013;<lpage>656</lpage>.</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Activation of autophagy contributes to the protective effects of lycopene against oxidative stress-induced apoptosis in rat chondrocytes</article-title>. <source>Phytotherapy Res.</source> <volume>35</volume> (<issue>7</issue>), <fpage>4032</fpage>&#x2013;<lpage>4045</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.7127</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Autophagy attenuates osteoarthritis in mice by inhibiting chondrocyte pyroptosis and improving subchondral bone remodeling</article-title>. <source>Bosn. J. Basic Med. Sci</source>. <pub-id pub-id-type="doi">10.17305/bjbms.2022.7677</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>H. L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Gowrisankar</surname>
<given-names>Y. V.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>P. J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Suppression of LPS-induced inflammation by chalcone flavokawain A through activation of nrf2/ARE-mediated antioxidant genes and inhibition of ROS/nf?b signaling pathways in primary splenocytes</article-title>. <source>Oxid. Med. Cell. Longev.</source> <volume>2020</volume>, <fpage>1</fpage>&#x2013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1155/2020/3476212</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>MicroRNA-495 enhances chondrocyte apoptosis, senescence and promotes the progression of osteoarthritis by targeting AKT1</article-title>. <source>Am. J. Transl. Res.</source> <volume>11</volume> (<issue>4</issue>), <fpage>2232</fpage>&#x2013;<lpage>2244</lpage>.</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mei</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-&#x3ba;B/MAPK signaling and protecting chondrocytes</article-title>. <source>Acta Pharm. Sin. B</source> <volume>9</volume> (<issue>5</issue>), <fpage>973</fpage>&#x2013;<lpage>985</lpage>. <pub-id pub-id-type="doi">10.1016/j.apsb.2019.01.015</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>